Medeva Ends Chiese MDI Tie-Up
UK pharmaceutical company Medeva and Chiese Farmaceutici of Italy have agreed mutually to end their 1994 agreement, which gave Medeva exclusive US distribution rights to the multi-dose dry-powder inhaler Pulvinal, a product currently under development for use with salbutamol and beclamethasone.
Medeva said that the regulatory requirements in the USA for registration of generic medicines in dry powder inhalers remain under review and are resulting in longer development timetables than it had originally envisaged. Chiese will progress development of the product itself.
Medeva stressed that this does not affect its plans to market a dry-powder inhaler in the UK and Europe. A license for the first of these products has recently been granted in the UK (Marketletter July 15), and the launch is scheduled for the first half of 1997, according to Medeva.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze